Epidemiological use of rectal proliferation measures

J. A. Baron, M. J. Wargovich, T. D. Tosteson, R. Sandler, Michael J Wargovich, R. Summers, R. Van Stolk, R. Rothstein, J. Weiss

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Measures of rectal mucosal proliferation have been developed and used in research clinical settings, but their utility for larger-scale epidemiological studies remains uncertain. We assessed the suitability of bromodeoxyuridine (BrdUrd) and proliferating cell nuclear antigen (PCNA)- labeling indices (LIs) in the setting of a multicenter clinical trial of adenoma recurrence. Subjects at participating practices were asked to permit biopsy of normal rectal mucosa during a colonoscopy scheduled for other reasons. PCNA and BrdUrd labeling was performed, and corresponding LIs were computed. In general, subjects were willing to undergo biopsy during their scheduled procedures; less than 10% refused. Specimen preparation for PCNA was acceptable; the mean number of scorable crypts (± SE) was 12.99 ± 0.37. Preparation for BrdUrd labeling was less successful, with a higher proportion of unscorable specimens and a lower mean number of scorable crypts. Among the 54 specimens with both LIs computed, the LI for PCNA was modestly higher than that for BrdUrd LI (4.1 ± 0.2 and 3.7 ± 0.2 respectively; P = 0.03). The rank order correlation between the two indices was 0.38. There was variation across centers in the PCNA LIs but few differences according to number of crypts scored. Measurement of rectal mucosal proliferation is feasible among endoscopy patients in large studies if PCNA is used; BrdUrd seems more difficult. The relationship between these two labels requires further study.

Original languageEnglish (US)
Pages (from-to)57-61
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume4
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

Proliferating Cell Nuclear Antigen
Bromodeoxyuridine
Biopsy
Colonoscopy
Adenoma
Endoscopy
Multicenter Studies
Epidemiologic Studies
Mucous Membrane
Clinical Trials
Recurrence
Research

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Baron, J. A., Wargovich, M. J., Tosteson, T. D., Sandler, R., Wargovich, M. J., Summers, R., ... Weiss, J. (1995). Epidemiological use of rectal proliferation measures. Cancer Epidemiology Biomarkers and Prevention, 4(1), 57-61.

Epidemiological use of rectal proliferation measures. / Baron, J. A.; Wargovich, M. J.; Tosteson, T. D.; Sandler, R.; Wargovich, Michael J; Summers, R.; Van Stolk, R.; Rothstein, R.; Weiss, J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 4, No. 1, 1995, p. 57-61.

Research output: Contribution to journalArticle

Baron, JA, Wargovich, MJ, Tosteson, TD, Sandler, R, Wargovich, MJ, Summers, R, Van Stolk, R, Rothstein, R & Weiss, J 1995, 'Epidemiological use of rectal proliferation measures', Cancer Epidemiology Biomarkers and Prevention, vol. 4, no. 1, pp. 57-61.
Baron JA, Wargovich MJ, Tosteson TD, Sandler R, Wargovich MJ, Summers R et al. Epidemiological use of rectal proliferation measures. Cancer Epidemiology Biomarkers and Prevention. 1995;4(1):57-61.
Baron, J. A. ; Wargovich, M. J. ; Tosteson, T. D. ; Sandler, R. ; Wargovich, Michael J ; Summers, R. ; Van Stolk, R. ; Rothstein, R. ; Weiss, J. / Epidemiological use of rectal proliferation measures. In: Cancer Epidemiology Biomarkers and Prevention. 1995 ; Vol. 4, No. 1. pp. 57-61.
@article{acb0aca14e144acd8e33788804d0d237,
title = "Epidemiological use of rectal proliferation measures",
abstract = "Measures of rectal mucosal proliferation have been developed and used in research clinical settings, but their utility for larger-scale epidemiological studies remains uncertain. We assessed the suitability of bromodeoxyuridine (BrdUrd) and proliferating cell nuclear antigen (PCNA)- labeling indices (LIs) in the setting of a multicenter clinical trial of adenoma recurrence. Subjects at participating practices were asked to permit biopsy of normal rectal mucosa during a colonoscopy scheduled for other reasons. PCNA and BrdUrd labeling was performed, and corresponding LIs were computed. In general, subjects were willing to undergo biopsy during their scheduled procedures; less than 10{\%} refused. Specimen preparation for PCNA was acceptable; the mean number of scorable crypts (± SE) was 12.99 ± 0.37. Preparation for BrdUrd labeling was less successful, with a higher proportion of unscorable specimens and a lower mean number of scorable crypts. Among the 54 specimens with both LIs computed, the LI for PCNA was modestly higher than that for BrdUrd LI (4.1 ± 0.2 and 3.7 ± 0.2 respectively; P = 0.03). The rank order correlation between the two indices was 0.38. There was variation across centers in the PCNA LIs but few differences according to number of crypts scored. Measurement of rectal mucosal proliferation is feasible among endoscopy patients in large studies if PCNA is used; BrdUrd seems more difficult. The relationship between these two labels requires further study.",
author = "Baron, {J. A.} and Wargovich, {M. J.} and Tosteson, {T. D.} and R. Sandler and Wargovich, {Michael J} and R. Summers and {Van Stolk}, R. and R. Rothstein and J. Weiss",
year = "1995",
language = "English (US)",
volume = "4",
pages = "57--61",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Epidemiological use of rectal proliferation measures

AU - Baron, J. A.

AU - Wargovich, M. J.

AU - Tosteson, T. D.

AU - Sandler, R.

AU - Wargovich, Michael J

AU - Summers, R.

AU - Van Stolk, R.

AU - Rothstein, R.

AU - Weiss, J.

PY - 1995

Y1 - 1995

N2 - Measures of rectal mucosal proliferation have been developed and used in research clinical settings, but their utility for larger-scale epidemiological studies remains uncertain. We assessed the suitability of bromodeoxyuridine (BrdUrd) and proliferating cell nuclear antigen (PCNA)- labeling indices (LIs) in the setting of a multicenter clinical trial of adenoma recurrence. Subjects at participating practices were asked to permit biopsy of normal rectal mucosa during a colonoscopy scheduled for other reasons. PCNA and BrdUrd labeling was performed, and corresponding LIs were computed. In general, subjects were willing to undergo biopsy during their scheduled procedures; less than 10% refused. Specimen preparation for PCNA was acceptable; the mean number of scorable crypts (± SE) was 12.99 ± 0.37. Preparation for BrdUrd labeling was less successful, with a higher proportion of unscorable specimens and a lower mean number of scorable crypts. Among the 54 specimens with both LIs computed, the LI for PCNA was modestly higher than that for BrdUrd LI (4.1 ± 0.2 and 3.7 ± 0.2 respectively; P = 0.03). The rank order correlation between the two indices was 0.38. There was variation across centers in the PCNA LIs but few differences according to number of crypts scored. Measurement of rectal mucosal proliferation is feasible among endoscopy patients in large studies if PCNA is used; BrdUrd seems more difficult. The relationship between these two labels requires further study.

AB - Measures of rectal mucosal proliferation have been developed and used in research clinical settings, but their utility for larger-scale epidemiological studies remains uncertain. We assessed the suitability of bromodeoxyuridine (BrdUrd) and proliferating cell nuclear antigen (PCNA)- labeling indices (LIs) in the setting of a multicenter clinical trial of adenoma recurrence. Subjects at participating practices were asked to permit biopsy of normal rectal mucosa during a colonoscopy scheduled for other reasons. PCNA and BrdUrd labeling was performed, and corresponding LIs were computed. In general, subjects were willing to undergo biopsy during their scheduled procedures; less than 10% refused. Specimen preparation for PCNA was acceptable; the mean number of scorable crypts (± SE) was 12.99 ± 0.37. Preparation for BrdUrd labeling was less successful, with a higher proportion of unscorable specimens and a lower mean number of scorable crypts. Among the 54 specimens with both LIs computed, the LI for PCNA was modestly higher than that for BrdUrd LI (4.1 ± 0.2 and 3.7 ± 0.2 respectively; P = 0.03). The rank order correlation between the two indices was 0.38. There was variation across centers in the PCNA LIs but few differences according to number of crypts scored. Measurement of rectal mucosal proliferation is feasible among endoscopy patients in large studies if PCNA is used; BrdUrd seems more difficult. The relationship between these two labels requires further study.

UR - http://www.scopus.com/inward/record.url?scp=0028877936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028877936&partnerID=8YFLogxK

M3 - Article

C2 - 7894325

AN - SCOPUS:0028877936

VL - 4

SP - 57

EP - 61

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -